Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash & Equivalents (2020 - 2025)

Caribou Biosciences has reported Cash & Equivalents over the past 6 years, most recently at $12.4 million for Q4 2025.

  • Quarterly Cash & Equivalents fell 24.14% to $12.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.4 million through Dec 2025, down 24.14% year-over-year, with the annual reading at $12.4 million for FY2025, 24.14% down from the prior year.
  • Cash & Equivalents was $12.4 million for Q4 2025 at Caribou Biosciences, up from $11.1 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $435.3 million in Q3 2021 and troughed at $46000.0 in Q2 2021.
  • The 5-year median for Cash & Equivalents is $52.0 million (2023), against an average of $85.5 million.
  • Year-over-year, Cash & Equivalents tumbled 99.86% in 2021 and then skyrocketed 243695.65% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $240.4 million in 2021, then tumbled by 75.73% to $58.3 million in 2022, then dropped by 12.3% to $51.2 million in 2023, then crashed by 68.15% to $16.3 million in 2024, then decreased by 24.14% to $12.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Cash & Equivalents are $12.4 million (Q4 2025), $11.1 million (Q3 2025), and $25.2 million (Q2 2025).